SGLT2 inhibitors, as first-line therapy for DKD, have attracted attention for their combined use with natural active compounds
Loss of CHCHD2 and CHCHD10 activates OMA1 peptidase to disrupt mitochondrial cristae phenocopying patient mutations
The FTC uses FDAs administrative delisting process to challenge improperly listed patents
Check Your Eligibility Free Consultation (Prospective Patients) Starting July 1, 2026 , Medicare Part D covers Wegovy, Zepbound, and Foundayo for weight loss through the new GLP-1 Bridge program
Marissa Liza: I think, you know, when we're talking about, are you talking about for myself or what I recommend to a patient
Whats more important with a breast lift is the appearance size is better addressed in a breast augmentation procedure